OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture, and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy--to-use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which is designed to make the provision of emergency oxygen safer, more accessible, and easier to use than traditional oxygen provision systems.
OXYS' products improve access to emergency oxygen that affects the survival, recovery, and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory, or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments.
OXYS manufactures its products at a manufacturing facility in Frisco, Texas. The product has also been deployed in several other countries, including Brazil, Israel, Turkey and South Africa.
- Approved by FDA for OTC Purchase
- Validated Breakthrough Lifesaving Technology
- Great Brand/Market Reputation
- Lighter, Safer, More Affordable and Easier to Use
- 9 Patents, 15+ Pending
- 6 New Complimentary Products Launched
- “No brainer” Combined with AEDs
- Large and Growing Markets
- New Future Products, Vertical Markets
- Thousands of Lives Already Saved
- 40+ U.S. Distribution Agreements
OXYS has developed a unique platform technology whereby medically pure oxygen is created instantly from two dry inert powders, allowing oxygen to be delivered on demand. Using this technology, the company has developed the OxySure Model 615.
With Model 615, there are no compressed tanks, no dials, no valves, no regulatory maintenance, no hydrostatic testing, no batteries, and no required training. The technology is both safe and easy-to-use for the layperson and is available over the counter. Like an AED or fire extinguisher, Model 615 can be placed just about anywhere a medical emergency might occur to help improve medical outcomes and save lives by bridging the gap between a medical emergency and the arrival of first responders on the scene.
(1. Plug in the Mask 2. Turn the Knob 3. Place the mask over the nose and mouth)
There is no storage of oxygen; the oxygen is created on demand. As a result, the Model 615 eliminates the dangers traditionally associated with compressed tanks.
Other unique characteristics:
- Non-Compressed Oxygen - No other product like it is available today. The Model 615 solves the obstacles of availability and widespread adoption by eliminating the hazards of traditional oxygen sources. Oxygen is produced by the Model 615 only after the system is activated.
- No Prescription Required - The Model 615 makes emergency oxygen available without a prescription.
- No Training Required – The Model 615 is user friendly, designed so that the average person with no medial or first-responder training can use the system.
- Replaceable Cartridge - An endless supply of oxygen is available limited only by the number of cartridges on-hand without the complications of maintenance and refilling cumbersome tanks.
- Lightweight and Portable - For the first time, oxygen is available in a lightweight and durable plastic housing, easily carried with the included shoulder strap.
- Public Access - The Model 615 now makes oxygen available in countless public access locations and high security environments such as airports without the hazards of compressed tanks.
- Disposal - Environmentally friendly, cartridges can be disposed of with household trash.
- Safety - The cartridge ingredients are completely inert until oxygen is produced. There is no storage of oxygen, making it the safest source of emergency oxygen.
Product Selling Points
OXYS’ Model 615 is a pioneering technology that is defining a new market with no direct competition, providing a solution to problems with existing emergency oxygen, such as:
- Explosion hazard
- Expensive to purchase and maintain
- No widespread consumer application
- Produces high heat
- Explosion hazard
- Highly toxic
OXYS is targeting enormous end markets that are at least as large as the install base for AEDs, which exceeds 2 million units, and potentially as large as the fire extinguisher base, which exceeds 100 million units in the U.S. (500+ million units globally).
Model 615 has already been cleared by the U.S. Food & Drug Administration for over-the-counter (OTC) sale without the need for a prescription, and is already in the commercialization phase.
Recurring Revenue Model
Model 615 consists of a reusable housing and a replaceable cartridge, which must be replaced after each use or upon expiry of a 2-year shelf life. Over time, this results in recurring revenues and greater earnings predictability.
OXYS’ “oxygen from powder” technology also allows the company to develop much needed solutions for other vertical markets such as aviation, mining, and sports & recreation markets.
OXYS has been primarily focused on establishing partnerships with distributors, as well as reaching out to large OEM customers that may be able to expand its presence in the marketplace.
The company’s aim is to bridge the gap between an emergency situation and the arrival of first responders. According to USA Today, this gap is currently an average 6-15 minutes. AEDs address this gap, but oxygen has always been missing. OXYS’ technology is applicable to an alarmingly high population of at-risk individuals:
- Cardiovascular Disease
- 40 Million Diagnosed
- 40 Million Undiagnosed
- Chronic Obstructive Pulmonary Disease (COPD)
- 16 Million Diagnosed
- 14 Million Undiagnosed
- 1.6 Million on Long Term Oxygen Therapy (Back-up)
- Asthma – 22.3 million
- General medical & civil emergencies
- Travelers to higher altitudes
- Private pilots – 400,000
- Individuals over the age of 50
OXYS’ Model 615 is currently installed internationally in a variety of locations, including:
- Colleges: UT, TCU, UTD, MSU, Purdue
- K-12 education
The company believes that its technology has potential for market placement in:
- 20,000,000 OSHA Compliant Buildings
- 116,000,000 Homes and Apartments
- 7,000+ MRI Centers
- POC Markets, Alternate Sites
- 100,000 K-12 Schools
- 6,000,000 Residential Swimming Pools
- 925,000 Restaurants
- 350,000 Manufacturing Facilities
- 325,000 Places of Worship
- 16,000 Golf Courses
- Airports, Public Use Facilities, Sports Facilities
OXYS believes that there is dire need for mandating emergency oxygen in schools, requiring that an FDA-cleared, non-compressed oxygen source suitable for use by lay rescuers be made widely available.
AEDs are currently mandated in schools in 24 states:
Oxygen administration is often the first requirement in a medical emergency. The standard of care (SOC) today for first responders is to administer oxygen immediately upon arrival. Having an AED nearby would enable nurses, teachers, school administrators, and athletic trainers to “bridge the gap” by applying oxygen sooner, improving medical outcomes and saving lives, as well as minimizing absenteeism and saving millions of dollars for school districts.
Growth Strategy & Sales Model
OXYS’ technologies target a number of enormous end markets. With plans to initially target the 102,265 educational campuses in the U.S., the 350,735 manufacturing facilities, the 350,000 churches, and the 950,000 restaurants, the company could see a relatively large installed base over the near-term.
In the long run, the company aims to place its technology in any public or private place where people are at risk. From recreational vehicles to restaurants to federal buildings, the potential end markets for the Model 615 are at least as numerous as AEDs (2+ million units) and potentially as large as fire extinguishers (100+ million) in the U.S. The markets outside of the U.S. increase the global market size for OXYS to at least 500+ million units.
The company aims to capitalize on these markets primarily through partnerships with distributors and OEM customers. To execute this goal, the company has created a blueprint for growth:
Increase Sales to Existing and New Customers
- Deeper and wider in education, commercial and government
- Enter new international territories
- Jumpstart mass “At Risk” markets
Introduce New Products / Services and Channels
- Program management
- Sports & recreation model, SCSR, Aviation
- Disposable model
Pursue Market Catalysts
- Insurance Reimbursements
- Legislation / Mandates
- Trade shows
- National Safety Congress, ECCU (US)
- Medica (Germany)
- RETTMobil (Germany)
- Hospitalar (Brazil)
- Industrial Hygiene news
- Sports magazines
- Education newsletters
In the next 3-5 years OXYS aims to add more than 100 new distributors and grow its direct sales force and strategic accounts teams to more than 500 individuals. OXYS also intends to pursue legislation and mandates that would require life-saving devices such as Model 615 in public facilities. In addition, OXYS will:
- Aggressively pursue 3 million+ unit AED companion market with 100 million+ unit general placement markets
- Pursue insurance reimbursement
- Execute rolling short form commercial campaign(s) targeting
- Penetrate new vertical mass markets such as military, mining, aviation, sports/recreation, skin care, wound care, and automotive
Julian T. Ross, MBA, Chairman & CEO
Julian T. Ross is the OxySure founder, technology developer (holds 9 patents), and CEO. He has more than 25 years of experience in technology, manufacturing, and finance. He has managed development of production capabilities, partnerships and alliances, managed the development of sales, distribution and licensing partnerships, raised in excess of $14 million in debt and equity to fund operations, and took OXYS public in 2011 through an S-1 registration with the Securities and Exchange Commission. Ross’ other experience includes: roll-up, technology companies; $315 million high yield debt offering (Merrill Lynch/Salomon Brothers in lead, plus Deutsche Morgan Grenfell, Nomura Securities).
Jeremy “Jerry” Jones, Director
Jeremy Jones has more than 35 years in healthcare leadership. He was former chairman/CEO of Apria Healthcare (sold to Blackstone for $1.7 billion) and chairman of On Assignment (ASGN), a $1.3 billion healthcare services leader. His current and former boards include: CombiMatrix Corp. (CBMX); Byram Healthcare Centers Inc. (chairman); (3) Lifecare Solutions, Inc. (chairman) (4) US Labs, Inc. (acquired by Lab Corp in 2005; (5) Cardium Healthcare (acquired by CenCorp Health in 2006). He was formerly chairman of the Health Industry Distributors Association (HIDA) and is founding chairman of the Home Oxygen Services Coalition. He has also received the Dr. Jonas Salk Memorial Mentor in Medicine Award from the March of Dimes.
Vicki Jones, MBA, Director
- 30+ years of experience in management, sales, and customer service in both B2B and B2C spaces
- SVP for AT&T, runs $11 Billion TV and Internet business; leads a team of 15,000 people
Don Reed, BA, BS – Director
- 40 years of experience in management, business development, operations, and mergers & acquisitions
- President, Agave Resources, LLC., Private Equity
Dr. Vincent Mosesso, Jr., MD, FACEP – Advisory Board
- Founder of Sudden Cardiac Arrest Association (SCAA)
- Medical director for Pre-hospital Care at the University of Pittsburgh Medical Center (UPMC)
- Associate professor of Emergency Medicine at the University of Pittsburgh School of Medicine
- "Physician of the Year," 1998, Pennsylvania Emergency Health Services Council
Dr. James R. Winn, MD – Advisory Board
- 38 years of experience in the healthcare industry, both as a policy maker and as a physician in practice
- Former CEO of the Federation of State Medical Boards (FSMB) of the United States
Dr. Thomas D. Franklin, Jr. – Advisory Board
- 40 years of experience in medical research, education and leadership
- Sr. Scientific Advisor to North Texas Enterprise Center for Medical Technology
- Former president of the Texas Health Research Institute
Dr. Jonathan E. Burke, DMD – Advisory Board
- Significant experience in hyperbaric oxygen therapy and received an Attending Hyperbaric Medicine Certificate in 1996
- Oral and maxillofacial surgeon for the Philadelphia Flyers and Phantoms professional hockey clubs since 1994
Dr. R. Dean White, D.D.S., M.S. – Advisory Board
- 35+ years of experience in medicine and private practice
- Past president of the American Board of Oral & Maxillofacial Surgeons